Mirum Pharmaceuticals Reports Strong 2025 Results, Issues Robust 2026 Sales Guidance, and Highlights Key Pipeline Catalysts
summarizeSummary
Mirum Pharmaceuticals 2025, net product sales , net loss . 2026 sales guidance $630 million to $650 million , LIVMARLI . 2026 , multiple late-stage clinical trial readouts , catalysts . cash position , financial flexibility .
check_boxKey Events
-
Strong 2025 Financial Performance
2025 $521.3 million, 2024 $336.4 million. LIVMARLI sales 69% year-over-year to $360.0 million.
-
Robust 2026 Sales Guidance
2026 $630 million to $650 million, commercial growth.
-
Key Pipeline Catalysts Expected in 2026
2026 multiple late-stage clinical trial readouts, Volixibat VISTAS study (PSC) topline data in Q2 2026, LIVMARLI EXPAND study topline data in Q4 2026, Brelovitug AZURE-1 and AZURE-4 studies (HDV) topline data in H2 2026.
-
Improved Financial Position
2025 net loss $23.363 million, 2024 $87.942 million. 2025 unrestricted cash, cash equivalents, and investments $391.4 million as of December 31, 2025.
auto_awesomeAnalysis
Mirum Pharmaceuticals 2025, net product sales , net loss . 2026 sales guidance $630 million to $650 million , LIVMARLI . 2026 , multiple late-stage clinical trial readouts , catalysts . cash position , financial flexibility .
在该文件披露时，MIRM的交易价格为$108.62，交易所为NASDAQ，所属行业为Life Sciences，市值约为$65亿。 52周交易区间为$36.88至$109.28。 这份文件被评估为积极市场情绪，重要性评分为8/10。